April 18, 2016 Quarterly Report – 2016 Q1
Posted at 10:13h
in quarterly-reports
Quarterly report Vaccibody - 2016 Q1...
March 1, 2016 Completion of enrolment according to the study protocol for the phase I part of the VB C-01 study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
Posted at 16:26h
in Uncategorized
Vaccibody AS announced today the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...
February 1, 2016 Vaccibody awarded NOK 20 million (USD 2.3 million) to develop patient-specific therapeutic cancer vaccines
Posted at 12:28h
in Uncategorized
Therapeutic vaccine company Vaccibody today announced that it has received a grant up to NOK 20 million (USD 2.3 million) over four years from the Norwegian Research Council ‘s BIA Program to develop therapeutic cancer vaccines based on each patient’s specific neoantigens. Neoantigens are tumour-...
September 14, 2015 Vaccibody AS announces vaccination of first patient in its phase I/IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
Posted at 05:00h
in Uncategorized
Vaccibody AS announced today vaccination of the first patient in its multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). Patients will receive...
August 12, 2015 Vaccibody AS announces approval to initiate its first clinical trial
Posted at 12:07h
in Uncategorized
Vaccibody AS is pleased to announce that it has received the approval from the regulatory authorities (Paul Ehrlich Institute), of its clinical trial application for VB10.16 immunotherapy, the company’s lead drug candidate for the treatment high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human...
June 30, 2015 VACCIBODY APPOINTS MARTIN BONDE AS CEO
Posted at 14:28h
in Uncategorized
The board of Vaccibody is pleased to announce Dr. Martin Bonde as the new CEO of the company from August 10th, 2015. Dr. Bonde has more than 25 years of international experience from the biotech industry. He started his career in Dako AS, followed by Ostemeter AS...
June 4, 2015 Vaccibody AS announces participation in a research project on veterinary vaccines receiving NOK 78 million from the EU Horizon 2020 program
Posted at 09:44h
in Uncategorized
Vaccibody AS is pleased to announce initiation of a new 4 year collaborative research project with the aim to improve animal production and health through development of improved vaccination strategies. The SAPHIR project brings together interdisciplinary expertise from 14 academic institutions, 5 small and medium-sized...
May 26, 2015 Vaccibody aquaculture research collaboration receives NOK 10 million from the Norwegian Research Council
Posted at 08:34h
in Uncategorized
The research collaboration “New Targeting Vaccines for Sustainable Aquaculture” has received a grant of NOK 10 Million through the Norwegian Research Council’s program Biotek2021. Vaccibody is a partner in the project together with The Norwegian Veterinary Institute, Pharmaq AS, Kjeller Innovasjon and Kongla AS. The...
February 23, 2015 Vaccibody AS announces filing of a Clinical Trial Application (CTA) to initiate the First in Man Clinical study of its lead Drug Candidate VB10.16
Posted at 12:44h
in Uncategorized
Vaccibody AS, a biopharmaceutical company focusing on immunotherapy and vaccines, is pleased to announce the filing of a CTA to initiate the first in man clinical study of its lead drug candidate VB10.16. The CTA was filed with the Paul Ehrlich Institute, the Federal German...
January 27, 2015 Vacant position- Researcher/Engineer Vaccines/Immunotherapy
Posted at 12:45h
in Uncategorized
Vaccibody is a vaccine company dedicated to the development of novel vaccines that overcome shortcomings of current vaccine technologies. The Company’s proprietary vaccine platform increases the antibody and T-cell responses leading to remarkably effective vaccines. Vaccibody plans to initiate its first clinical trial with a...